Department of Internal Medicine
Bradley S. Dixon, M.D.
Dr. Dixon's research focuses on vascular biology, problems with hemodialysis vascular access failure and clinical trials in kidney disease. Earlier laboratory investigation focused on the potential role of bradykinin in regulating vascular smooth muscle proliferation and the development of neointimal hyperplasia. It was discovered that the bradykinin B1 receptor regulated Cyc D and Kip1, controlling cell cycle progression at the G1 to S phase of the cell cycle. Local generation of kinins may be important in regulating neointimal hyperplasia after vascular injury.
Hemodialysis vascular access failure involves neointimal hyperplasia leading to vascular stenosis and thrombosis. Our clinical trials group participated in NIH-sponsored multicentered clinical trials of treatments to prevent vascular access failure. These studies demonstrated that antiplatelet agents prolonged primary unassisted patency of hemodialysis grafts and prevented early thrombosis of arteriovenous fistulas but did not increase the fistula maturation. Ongoing studies are looking at novel therapies to improve fistula maturation. Further ongoing clinical trials are looking at therapies to slow the progression of diabetic nephropathy. Clinical research under Dr Dixon’s direction is also examining the effect of various renal replacement therapies on cognitive function in CKD and understanding the mechanism of endothelial dysfunction in patients with CKD.
Honors, Awards, and Organizations
- American Society for Nephrology
- American Heart Association